Roy C. Martin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Roy C. Martin has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Jane B. Allendorfer
Department of Neurology, University of Alabama at Birmingham
3 shared publications E. Faught
UAB Epilepsy Center, Department of Neurology, University of Alabama at Birmingham, USA
2 shared publications- Jerzy P. Szaflarski
Department of Neurology University of Alabama at Birmingham Birmingham Alabama USA
2 shared publications - Robert C. Knowlton
Department of Neurology University of California, San Francisco San Francisco California USA
2 shared publications - Ruben Kuzniecky
Department of Neurology, Hofstra-Northwell Medical School, New York, NY, USA
2 shared publications - Adam Gerstenecker
Department of Neurology, University of Alabama at Birmingham, Birmingham, USA
1 shared publication
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in Epilepsia Open
Neurometabolite abnormalities and associations with epilepsy duration and cognition in patients with idiopathic generalized epilepsies
Objective: This study investigated whether idiopathic generalized epilepsies (IGEs) are associated with neuroinflammation by measuring neurometabolite levels and brain temperature using whole‐brain magnetic resonance spectroscopy imaging (MRSI). We compared patients with IGEs to healthy controls (HCs), and in IGEs examined relationships with seizure control, MRSI markers, epilepsy duration, and cognitive performance. Methods: Seventeen patients with IGEs and 15 HCs underwent 3T‐MRI scans. IGEs were also administered the Montreal Cognitive Assessment (MoCA) and Flanker test. Whole‐brain 1 H‐MRSI provided metabolite and water maps. Levels for myo‐inositol (MI; glial marker), glutamate‐glutamine complex (Glx), and N‐acetylaspartate (NAA) were normalized to creatine (Cr) levels. Brain temperature was obtained by frequency difference between water and Cr. IGEs were stratified into seizure‐free (IGE−) and treatment‐resistant (IGE+) groups. Group analyses were performed using permutation‐based threshold‐free cluster enhancement (TFCE) within bilateral regions of interest: anterior cingulate cortex (ACC), posterior cingulate cortex (PCC), hippocampus, parietal cortex, and thalami. Results: Compared with HCs, IGEs showed higher MI/Cr in the parietal cortex, PCC, and thalamus; higher hippocampus Glx/Cr; and lower parietal cortex NAA/Cr. Brain temperature did not differ between groups. IGE− exhibited higher hippocampal NAA/Cr and better MoCA scores than IGE+. Longer epilepsy duration was associated with lower NAA/Cr in the ACC and PCC, and parietal cortex, as well as lower Glx/Cr in the ACC, PCC, parietal cortex, and hippocampus. Lower NAA/Cr in the ACC, PCC, hippocampus, and thalamus, together with higher thalamus MI/Cr, was associated with lower MoCA scores in IGEs. Lower NAA/Cr in the ACC, thalamus, and hippocampus was associated with poorer Flanker performance in IGEs. Significance: We provide novel evidence of neurometabolic abnormalities in IGEs. The associations between metabolite levels and clinical and cognitive variables suggest potential biomarkers for disease progression and treatment response. Furthermore, these results highlight the roles of abnormal glial activation, neuronal loss, and hyperexcitability in IGE pathophysiology. Plain Language Summary: We compared patients with idiopathic generalized epilepsies (IGEs) to healthy controls (HCs) to investigate brain chemistry and temperature differences and their relationships to seizure control, epilepsy duration, and cognitive performance. We found group differences in brain N‐acetylaspartate (NAA; neuronal marker), myo‐inositol (MI; glial cell marker), and glutamate/glutamine (Glx; excitatory neurotransmission) levels, but not in brain temperature. Longer epilepsy duration was associated with brain chemistry levels. In IGEs, lower NAA levels and higher MI levels were associated with worse cognitive performance. This study highlights the roles of abnormal glial activation, neuronal loss, and hyperexcitability in epilepsy duration and cognition in IGEs.
- 8 October 2026
- Published by Wiley in Epilepsia Open
Open AccessNeurometabolite abnormalities and associations with epilepsy duration and cognition in patients with idiopathic generalized epilepsies
Objective: This study investigated whether idiopathic generalized epilepsies (IGEs) are associated with neuroinflammation by measuring neurometabolite levels and brain temperature using whole‐brain magnetic resonance spectroscopy imaging (MRSI). We compared patients with IGEs to healthy controls (HCs), and in IGEs examined relationships with seizure control, MRSI markers, epilepsy duration, and cognitive performance. Methods: Seventeen patients with IGEs and 15 HCs underwent 3T‐MRI scans. IGEs were also administered the Montreal Cognitive Assessment (MoCA) and Flanker test. Whole‐brain 1 H‐MRSI provided metabolite and water maps. Levels for myo‐inositol (MI; glial marker), glutamate‐glutamine complex (Glx), and N‐acetylaspartate (NAA) were normalized to creatine (Cr) levels. Brain temperature was obtained by frequency difference between water and Cr. IGEs were stratified into seizure‐free (IGE−) and treatment‐resistant (IGE+) groups. Group analyses were performed using permutation‐based threshold‐free cluster enhancement (TFCE) within bilateral regions of interest: anterior cingulate cortex (ACC), posterior cingulate cortex (PCC), hippocampus, parietal cortex, and thalami. Results: Compared with HCs, IGEs showed higher MI/Cr in the parietal cortex, PCC, and thalamus; higher hippocampus Glx/Cr; and lower parietal cortex NAA/Cr. Brain temperature did not differ between groups. IGE− exhibited higher hippocampal NAA/Cr and better MoCA scores than IGE+. Longer epilepsy duration was associated with lower NAA/Cr in the ACC and PCC, and parietal cortex, as well as lower Glx/Cr in the ACC, PCC, parietal cortex, and hippocampus. Lower NAA/Cr in the ACC, PCC, hippocampus, and thalamus, together with higher thalamus MI/Cr, was associated with lower MoCA scores in IGEs. Lower NAA/Cr in the ACC, thalamus, and hippocampus was associated with poorer Flanker performance in IGEs. Significance: We provide novel evidence of neurometabolic abnormalities in IGEs. The associations between metabolite levels and clinical and cognitive variables suggest potential biomarkers for disease progression and treatment response. Furthermore, these results highlight the roles of abnormal glial activation, neuronal loss, and hyperexcitability in IGE pathophysiology. Plain Language Summary: We compared patients with idiopathic generalized epilepsies (IGEs) to healthy controls (HCs) to investigate brain chemistry and temperature differences and their relationships to seizure control, epilepsy duration, and cognitive performance. We found group differences in brain N‐acetylaspartate (NAA; neuronal marker), myo‐inositol (MI; glial cell marker), and glutamate/glutamine (Glx; excitatory neurotransmission) levels, but not in brain temperature. Longer epilepsy duration was associated with brain chemistry levels. In IGEs, lower NAA levels and higher MI levels were associated with worse cognitive performance. This study highlights the roles of abnormal glial activation, neuronal loss, and hyperexcitability in epilepsy duration and cognition in IGEs.
- Open Access
Differential cognitive effects of unilateral left and right subthalamic nucleus deep brain stimulation for Parkinson disease
Objective: To investigate hemispheric effects of directional versus ring subthalamic nucleus (STN) deep brain stimulation (DBS) surgery on cognitive function in patients with advanced Parkinson’s disease (PD). Methods: We examined 31 PD patients (Left STN n = 17; Right STN n = 14) who underwent unilateral subthalamic nucleus (STN) DBS as part of a NIH-sponsored randomized, cross-over, double-blind (ring vs directional) clinical trial. Outcome measures were tests of verbal fluency, auditory-verbal memory, and response inhibition. First, all participants were pooled together to study the effects of directional versus ring stimulation. Then, we stratified the groups by surgery hemisphere and studied the longitudinal changes in cognition post-unilateral STN DBS. Results: Relative to pre-DBS cognitive baseline performances, there were no group changes in cognition following unilateral DBS for either directional or ring stimulation. However, assessment of unilateral DBS by hemisphere revealed a different pattern. The left STN DBS group had lower verbal fluency than the right STN group ( t (20.66 = -2.50, p = 0.02). Over a period of eight months post-DBS, verbal fluency declined in the left STN DBS group ( p = 0.013) and improved in the right STN DBS group over time ( p < .001). Similarly, response inhibition improved following right STN DBS ( p = 0.031). Immediate recall did not significantly differ over time, nor was it affected by implant hemisphere, but delayed recall equivalently declined over time for both left and right STN DBS groups (left STN DBS p = 0.001, right STN DBS differ from left STN DBS p = 0.794). Conclusions: Directional and ring DBS did not differentially or adversely affect cognition over time. Regarding hemisphere effects, verbal fluency decline was observed in those who received left STN DBS, along with the left and right STN DBS declines in delayed memory. The left STN DBS verbal fluency decrement is consistent with prior bilateral DBS research, likely reflecting disruption of the basal-ganglia-thalamocortical network connecting STN and inferior frontal gyrus. Interestingly, we found an improvement in verbal fluency and response inhibition following right STN DBS. It is possible that unilateral STN DBS, particularly in the right hemisphere, may mitigate cognitive decline.
Open AccessDifferential cognitive effects of unilateral left and right subthalamic nucleus deep brain stimulation for Parkinson disease
Objective: To investigate hemispheric effects of directional versus ring subthalamic nucleus (STN) deep brain stimulation (DBS) surgery on cognitive function in patients with advanced Parkinson’s disease (PD). Methods: We examined 31 PD patients (Left STN n = 17; Right STN n = 14) who underwent unilateral subthalamic nucleus (STN) DBS as part of a NIH-sponsored randomized, cross-over, double-blind (ring vs directional) clinical trial. Outcome measures were tests of verbal fluency, auditory-verbal memory, and response inhibition. First, all participants were pooled together to study the effects of directional versus ring stimulation. Then, we stratified the groups by surgery hemisphere and studied the longitudinal changes in cognition post-unilateral STN DBS. Results: Relative to pre-DBS cognitive baseline performances, there were no group changes in cognition following unilateral DBS for either directional or ring stimulation. However, assessment of unilateral DBS by hemisphere revealed a different pattern. The left STN DBS group had lower verbal fluency than the right STN group ( t (20.66 = -2.50, p = 0.02). Over a period of eight months post-DBS, verbal fluency declined in the left STN DBS group ( p = 0.013) and improved in the right STN DBS group over time ( p < .001). Similarly, response inhibition improved following right STN DBS ( p = 0.031). Immediate recall did not significantly differ over time, nor was it affected by implant hemisphere, but delayed recall equivalently declined over time for both left and right STN DBS groups (left STN DBS p = 0.001, right STN DBS differ from left STN DBS p = 0.794). Conclusions: Directional and ring DBS did not differentially or adversely affect cognition over time. Regarding hemisphere effects, verbal fluency decline was observed in those who received left STN DBS, along with the left and right STN DBS declines in delayed memory. The left STN DBS verbal fluency decrement is consistent with prior bilateral DBS research, likely reflecting disruption of the basal-ganglia-thalamocortical network connecting STN and inferior frontal gyrus. Interestingly, we found an improvement in verbal fluency and response inhibition following right STN DBS. It is possible that unilateral STN DBS, particularly in the right hemisphere, may mitigate cognitive decline.
- 1 May 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 118, 107900
Relationships between cognitive function, seizure control, and self-reported leisure-time exercise in epilepsy
- 1 May 2021
- Published by Elsevier in Epilepsy & Behavior
- Vol. 118, 107900
Relationships between cognitive function, seizure control, and self-reported leisure-time exercise in epilepsy
- 1 November 2020
- Published by Elsevier in Epilepsy & Behavior
- Vol. 112, 107358
Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsy
- 1 November 2020
- Published by Elsevier in Epilepsy & Behavior
- Vol. 112, 107358
Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsy
- Open Access
- 20 May 2020
- Published by SAGE Publications in Epilepsy Currents
- Vol. 20 (4) , 196-198
AEDs and Cognition: One Small Fish in a Very Large Pond?
Antiepileptic Drugs Are Not Independently Associated With Cognitive Dysfunction Foster E, Malpas CB, Ye K, et al. Neurology . 2020;94:e1051-e1061. doi: 10.1212/WNL.0000000000009061 . Objective: To test the hypothesis that individual antiepileptic drugs (AEDs) are not associated with cognitive impairment beyond other clinically relevant factors, we performed a cross-sectional study of patients admitted to an inpatient video-electroencephalogram monitoring unit. Methods: We prospectively enrolled patients admitted to an inpatient specialist epilepsy program between 2009 and 2016. Assessments included objective cognitive function, quality of life subscales for subjective cognitive function, and questionnaires for anxiety and depressive symptoms. Bayesian model averaging identified predictors of cognitive function. Bayesian model selection approach investigated effect of individual AEDs on cognition. Conventional frequentist analyses were also performed. Results: A total of 331 patients met inclusion criteria. Mean age was 39.3 years and 61.9% of patients were women. A total of 45.0% of patients were prescribed AED polypharmacy, 25.1% AED monotherapy, and 29.9% no AED. Age, seizure frequency, and a diagnosis of concomitant epilepsy and psychogenic nonepileptic seizure were predictors of objective cognitive function. Depression, anxiety, and seizure frequency were predictors of subjective cognitive function. Individual AEDs were not independently associated with impaired cognitive function beyond other clinically relevant variables. Conclusions: This study found that no AED was independently associated with cognitive dysfunction. Significant determinants of objective and subjective cognitive dysfunction included seizure frequency and depression, respectively. These findings suggest that optimizing therapy to prevent seizures is not likely to occur at the expense of cognitive function.
- 20 May 2020
- Published by SAGE Publications in Epilepsy Currents
- Vol. 20 (4) , 196-198
Open AccessAEDs and Cognition: One Small Fish in a Very Large Pond?
Antiepileptic Drugs Are Not Independently Associated With Cognitive Dysfunction Foster E, Malpas CB, Ye K, et al. Neurology . 2020;94:e1051-e1061. doi: 10.1212/WNL.0000000000009061 . Objective: To test the hypothesis that individual antiepileptic drugs (AEDs) are not associated with cognitive impairment beyond other clinically relevant factors, we performed a cross-sectional study of patients admitted to an inpatient video-electroencephalogram monitoring unit. Methods: We prospectively enrolled patients admitted to an inpatient specialist epilepsy program between 2009 and 2016. Assessments included objective cognitive function, quality of life subscales for subjective cognitive function, and questionnaires for anxiety and depressive symptoms. Bayesian model averaging identified predictors of cognitive function. Bayesian model selection approach investigated effect of individual AEDs on cognition. Conventional frequentist analyses were also performed. Results: A total of 331 patients met inclusion criteria. Mean age was 39.3 years and 61.9% of patients were women. A total of 45.0% of patients were prescribed AED polypharmacy, 25.1% AED monotherapy, and 29.9% no AED. Age, seizure frequency, and a diagnosis of concomitant epilepsy and psychogenic nonepileptic seizure were predictors of objective cognitive function. Depression, anxiety, and seizure frequency were predictors of subjective cognitive function. Individual AEDs were not independently associated with impaired cognitive function beyond other clinically relevant variables. Conclusions: This study found that no AED was independently associated with cognitive dysfunction. Significant determinants of objective and subjective cognitive dysfunction included seizure frequency and depression, respectively. These findings suggest that optimizing therapy to prevent seizures is not likely to occur at the expense of cognitive function.
- Open Access
- 13 August 2015
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 31 (4) , 406-411
Introducing demographic corrections for the 10/36 Spatial Recall Test
Objective The 10/36 Spatial Recall Test is a measure of visuospatial memory and has been recommended for inclusion when administering a brief cognitive assessment to patients with multiple sclerosis by multiple groups. However, a notable limitation of the measure includes a lack of normative data with demographic corrections. Thus, the primary objective of the current study was to examine demographic influences on the 10/36 Spatial Recall Test and to introduce demographically corrected normative data for the instrument. Methods Data were collected from 116 participants over the age of 50 years. All study participants were free of any neurologic disease or disorder and classified as cognitively intact by a consensus conference team that was comprised of neurologists and neuropsychologists. All study participants were administered a neuropsychological evaluation that included the 10/36 Spatial Recall Test Version A at the baseline visit. Results 10/36 Spatial Recall Test scores were affected by age, education, and race. Gender effects were not observed. Given these effects, regression equations were used to correct for the effects of demographic variables. The z‐scores obtained from these corrections were not significantly influenced by demographical variables. Conclusion The demographic corrections introduced in this paper offer the possibility to enhance the clinical utility of the 10/36 Spatial Recall Test. Copyright © 2015 John Wiley & Sons, Ltd.
- 13 August 2015
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 31 (4) , 406-411
Open AccessIntroducing demographic corrections for the 10/36 Spatial Recall Test
Objective The 10/36 Spatial Recall Test is a measure of visuospatial memory and has been recommended for inclusion when administering a brief cognitive assessment to patients with multiple sclerosis by multiple groups. However, a notable limitation of the measure includes a lack of normative data with demographic corrections. Thus, the primary objective of the current study was to examine demographic influences on the 10/36 Spatial Recall Test and to introduce demographically corrected normative data for the instrument. Methods Data were collected from 116 participants over the age of 50 years. All study participants were free of any neurologic disease or disorder and classified as cognitively intact by a consensus conference team that was comprised of neurologists and neuropsychologists. All study participants were administered a neuropsychological evaluation that included the 10/36 Spatial Recall Test Version A at the baseline visit. Results 10/36 Spatial Recall Test scores were affected by age, education, and race. Gender effects were not observed. Given these effects, regression equations were used to correct for the effects of demographic variables. The z‐scores obtained from these corrections were not significantly influenced by demographical variables. Conclusion The demographic corrections introduced in this paper offer the possibility to enhance the clinical utility of the 10/36 Spatial Recall Test. Copyright © 2015 John Wiley & Sons, Ltd.
- 1 December 2004
- Published by Elsevier in Epilepsy Research
- Vol. 62 (2-3) , 119-124
Chronic temporal lobe epilepsy: spatial extent and degree of metabolic dysfunction studied with magnetic resonance spectroscopy (MRS)
- 1 December 2004
- Published by Elsevier in Epilepsy Research
- Vol. 62 (2-3) , 119-124
Chronic temporal lobe epilepsy: spatial extent and degree of metabolic dysfunction studied with magnetic resonance spectroscopy (MRS)
- 27 April 2004
- Published by Wolters Kluwer Health in Neurology
- Vol. 62 (8) , 1352-1356
Eclampsia, hippocampal sclerosis, and temporal lobe epilepsy
Background: Up to 30% of patients with temporal lobe epilepsy (TLE) have no identifiable risk factors. Objectives: To report nine patients with TLE who had a history of eclampsia as the only risk factor for epilepsy and to investigate whether this possible association existed in a larger cohort of women with surgically treated TLE. Methods: The clinical data, video-EEG, neuroimaging, and neuropathology of 195 consecutive women undergoing anterior temporal lobectomy (ATL) were reviewed. Risk factors for TLE, age at epilepsy onset, and occurrence of pregnancy were identified in each patient. Results: Twenty-six women had no identifiable risk factors or seizures following a pregnancy. Nine of the 26 women had a history of eclampsia. The median age at the time of eclampsia was 16 years, and the latent period between the occurrence of eclampsia and onset of epilepsy ranged from 1 month to 2 years. The clinical, EEG, MRI, and neuropathologic findings were typical of hippocampal sclerosis (HS) and other than age at onset were no different from those of noneclampsia ATL patients. At mean follow-up of 57 months, seven patients were seizure-free and the other two markedly improved. Conclusion: Eclampsia may be a risk factor for TLE and HS.
- 27 April 2004
- Published by Wolters Kluwer Health in Neurology
- Vol. 62 (8) , 1352-1356
Eclampsia, hippocampal sclerosis, and temporal lobe epilepsy
Background: Up to 30% of patients with temporal lobe epilepsy (TLE) have no identifiable risk factors. Objectives: To report nine patients with TLE who had a history of eclampsia as the only risk factor for epilepsy and to investigate whether this possible association existed in a larger cohort of women with surgically treated TLE. Methods: The clinical data, video-EEG, neuroimaging, and neuropathology of 195 consecutive women undergoing anterior temporal lobectomy (ATL) were reviewed. Risk factors for TLE, age at epilepsy onset, and occurrence of pregnancy were identified in each patient. Results: Twenty-six women had no identifiable risk factors or seizures following a pregnancy. Nine of the 26 women had a history of eclampsia. The median age at the time of eclampsia was 16 years, and the latent period between the occurrence of eclampsia and onset of epilepsy ranged from 1 month to 2 years. The clinical, EEG, MRI, and neuropathologic findings were typical of hippocampal sclerosis (HS) and other than age at onset were no different from those of noneclampsia ATL patients. At mean follow-up of 57 months, seven patients were seizure-free and the other two markedly improved. Conclusion: Eclampsia may be a risk factor for TLE and HS.